Influenza B virus B/Phuket/3073/2013 live (attenuated) antigen

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Brand Names
FluMist Quadrivalent
Generic Name
Influenza B virus B/Phuket/3073/2013 live (attenuated) antigen
DrugBank Accession Number
DB11036
Background

A seasonally-specific component of the influenza vaccine. The influenza vaccine, also known as the "flu shot", is a vaccine that protects against infection from the influenza viruses. Vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen". This defence includes the production of humoral immunity through the development of antibodies (through memory B cells) and of cell-mediated immunity through the production of T-lymphocytes. Upon re-exposure to infectious influenza virus, the immune system is prepared to identify and destroy the virus as there are circulating antibodies that recognize that particular component of the virus that it was previously exposed to.

There are two basic types of vaccines available: inactivated influenza vaccine (IIV) and live attenuated influenza vaccine (LAIV). Inactivated vaccines contain a virus particle that has been grown in media and then subsequently killed, or inactivated, through exposure to heat or chemicals such as formaldehyde 3. Inactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals. In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques. Live vaccines maintain their replicative ability.

Type
Biotech
Groups
Approved
Biologic Classification
Vaccines
Attenuated
Synonyms
  • influenza B virus B/Phuket/3073/2013 antigen

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Associated Conditions
Indication TypeIndicationCombined Product DetailsApproval LevelAge GroupPatient CharacteristicsDose Form
Used in combination to preventFlu caused by influenzaCombination Product in combination with: Influenza B virus B/Washington/02/2019 recombinant hemagglutinin antigen (DB15702), Influenza A virus A/South Australia/34/2019 IVR-197 (H3N2) antigen (formaldehyde inactivated) (DB15621), Influenza A virus A/Brisbane/02/2018 IVR-190 (H1N1) antigen (formaldehyde inactivated) (DB15515)•••••••••••••••••••••• ••••••••••• ••••••••••
Used in combination to preventFlu caused by influenzaCombination Product in combination with: Influenza A virus A/Brisbane/02/2018 (H1N1) recombinant hemagglutinin antigen (DB15517), Influenza B virus B/Washington/02/2019 recombinant hemagglutinin antigen (DB15702), Influenza A virus A/South Australia/34/2019 IVR-197 (H3N2) antigen (formaldehyde inactivated) (DB15621)••••••••••••••••••••••
Used in combination to preventFlu caused by influenzaCombination Product in combination with: Influenza B virus B/Darwin/7/2019 antigen (MDCK cell derived, propiolactone inactivated) (DB15709), Influenza A virus A/Delaware/39/2019 (H3N2) antigen (MDCK cell derived, propiolactone inactivated) (DB15708), Influenza A virus A/Hawaii/70/2019 (H1N1) recombinant hemagglutinin antigen (DB15700)•••••••••••••••••••••• ••••••••••
Used in combination to preventFlu caused by influenzaCombination Product in combination with: Influenza A virus A/Hawaii/66/2019 (H1N1) live (attenuated) antigen (DB15756), Influenza A virus A/Hong Kong/2671/2019 (H3N2) live (attenuated) antigen (DB15757), Influenza B virus B/Washington/02/2019 live (attenuated) antigen (DB15758)•••••••••••••••••
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Products

Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing EndRegionImage
FLUARIX TETRAInfluenza B virus B/Phuket/3073/2013 live (attenuated) antigen (15 mcg) + Influenza A virus A/Brisbane/02/2018 IVR-190 (H1N1) antigen (formaldehyde inactivated) (15 mcg) + Influenza A virus A/South Australia/34/2019 IVR-197 (H3N2) antigen (formaldehyde inactivated) (15 mcg) + Influenza B virus B/Washington/02/2019 recombinant hemagglutinin antigen (15 mcg)SuspensionIntramuscular2015-08-032019-06-12Colombia flag
FLUCELVAX TETRAInfluenza B virus B/Phuket/3073/2013 live (attenuated) antigen (15 mcg) + Influenza A virus A/Delaware/39/2019 (H3N2) antigen (MDCK cell derived, propiolactone inactivated) (15 mcg) + Influenza A virus A/Hawaii/70/2019 (H1N1) recombinant hemagglutinin antigen (15 mcg) + Influenza B virus B/Darwin/7/2019 antigen (MDCK cell derived, propiolactone inactivated) (15 mcg)Injection, suspensionIntramuscularSeqirus Netherlands B.V.2019-08-08Not applicableItaly flag
FLUCELVAX TETRAInfluenza B virus B/Phuket/3073/2013 live (attenuated) antigen (15 mcg) + Influenza A virus A/Delaware/39/2019 (H3N2) antigen (MDCK cell derived, propiolactone inactivated) (15 mcg) + Influenza A virus A/Hawaii/70/2019 (H1N1) recombinant hemagglutinin antigen (15 mcg) + Influenza B virus B/Darwin/7/2019 antigen (MDCK cell derived, propiolactone inactivated) (15 mcg)Injection, suspensionIntramuscularSeqirus Netherlands B.V.2019-03-15Not applicableItaly flag
FLUCELVAX TETRAInfluenza B virus B/Phuket/3073/2013 live (attenuated) antigen (15 mcg) + Influenza A virus A/Delaware/39/2019 (H3N2) antigen (MDCK cell derived, propiolactone inactivated) (15 mcg) + Influenza A virus A/Hawaii/70/2019 (H1N1) recombinant hemagglutinin antigen (15 mcg) + Influenza B virus B/Darwin/7/2019 antigen (MDCK cell derived, propiolactone inactivated) (15 mcg)Injection, suspensionIntramuscularSeqirus Netherlands B.V.2019-08-08Not applicableItaly flag
Fluenz TetraInfluenza B virus B/Phuket/3073/2013 live (attenuated) antigen (10000000 FFU/0.2ml) + Influenza A virus A/Hawaii/66/2019 (H1N1) live (attenuated) antigen (10000000 FFU/0.2ml) + Influenza A virus A/Hong Kong/2671/2019 (H3N2) live (attenuated) antigen (10000000 FFU/0.2ml) + Influenza B virus B/Washington/02/2019 live (attenuated) antigen (10000000 FFU/0.2ml)Astra Zeneca Ab2021-02-09Not applicableEU flag

Categories

Drug Categories
Not Available
Classification
Not classified
Affected organisms
Not Available

Chemical Identifiers

UNII
91E648A88W
CAS number
Not Available

References

General References
Not Available
RxNav
1657228

Clinical Trials

Clinical Trials
Clinical Trial & Rare Diseases Add-on Data Package
Explore 4,000+ rare diseases, orphan drugs & condition pairs, clinical trial why stopped data, & more. Preview package
PhaseStatusPurposeConditionsCountStart DateWhy Stopped100+ additional columns
4Active Not RecruitingTreatmentFlu caused by Influenza1somestatusstop reasonjust information to hide
4CompletedHealth Services ResearchInfluenza, Human / Pneumonia1somestatusstop reasonjust information to hide
4CompletedPreventionFlu caused by Influenza / Healthy Volunteers (HV)1somestatusstop reasonjust information to hide
4CompletedPreventionInfluenza, Human1somestatusstop reasonjust information to hide
3CompletedPreventionFlu caused by Influenza3somestatusstop reasonjust information to hide

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
Injection, suspensionIntramuscular
SprayNasal
SuspensionIntramuscular
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Drug created at December 01, 2015 20:05 / Updated at June 12, 2020 16:53